Join the club for FREE to access the whole archive and other member benefits.

Underdog pharmaceuticals secures $10m funding from Kizoo ventures


Key points from article :

Kizoo Technology Capital Group led the Series Seed II round for Underdog Pharmaceuticals.

Underdog aims for the first true disease-modifying treatments for age-related conditions.

Custom-engineered cyclodextrins tackle cholesterol derivatives such as 7-ketocholesterol.

Awarded the Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP).

This will enable faster patient access to its ground-breaking treatment for the prevention of heart attacks and stroke.

The company expects to begin clinical trials in 2023.

Kizoo believes that this industry that will eventually outgrow today’s largest technology markets.

Mike Kope, Underdog Co-CEO, said: “The ILAP award together with the new funds will enable us to further advance to deliver a simple and affordable preventive therapy for the world.”

Funds to bring affordable and effective age-related therapies to the public

Mentioned in this article:

Click on resource name for more details.

Cyclarity Therapeutics

Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.

KIZOO Technology Ventures

Company providing financing and its focus is on rejuvenation biotech

Michael Kope

Co-Chief Executive Officer and Co-founder Underdog Pharmaceuticals